Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Conference Coverage (AACR)
Phase I Trial of GD3-Lactone-KLH Melanoma Vaccine Presented
May 26th, 1997
Results of a Phase I clinical trial of the GD3-Lactone-KLH conjugate vaccine with the immunological adjuvant QS-21 were presented at the American Association for Cancer Research conference, held April 12-16, 1997, in San Diego, California. "The significant finding in this study is that for the first time, an immune response against GD3 was observed in all patients vaccinated with our new preparation," reported Dr. Govindaswami Ragupathi during a press briefing. He explained that the GD3, as well as GD2 and GM2, are gangliosides that belong to a class of carbohydrate antigens and that carbohydrates are the most abundantly expressed antigens on the...
Source: Cancer Weekly (1997-05-26)
|
